|
- | mirvaso
MIRVASO® (brimonidine) topical gel, 0 33%* is the first FDA-approved treatment developed and indicated for persistent facial redness of rosacea
- Using MIRVASO | mirvaso
Indication: MIRVASO® (brimonidine) topical gel, 0 33%* is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older
- About MIRVASO | mirvaso
Get ready for real redness relief: MIRVASO® (brimonidine) topical gel, 0 33%* is the first FDA-approved medication developed and indicated for the persistent (nontransient) facial redness of rosacea MIRVASO Topical Gel has been proven to continue to give consistent results, month after month † MIRVASO Topical Gel Key Facts
- FAQ - mirvaso
Q: What is MIRVASO Topical Gel? MIRVASO® (brimonidine) topical gel, 0 33%* is formulated especially to treat the persistent (nontransient) facial redness of rosacea in people 18 years and older Q: How does MIRVASO Topical Gel work? MIRVASO Topical Gel is believed to reduce excessive blood flow that's associated with rosacea redness
- About Rosacea - mirvaso
Important Safety Information Indication: MIRVASO® (brimonidine) topical gel, 0 33%* is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older
- hcp - mirvaso
Indication: MIRVASO® (brimonidine) topical gel, 0 33%* is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older
- About MIRVASO HCP | mirvaso
Prescribe a treatment that was specially formulated to address their condition: MIRVASO® (brimonidine) topical gel, 0 33%* is the first FDA-approved treatment specifically developed and indicated for the facial erythema of rosacea 1 The active ingredient in MIRVASO Topical Gel is brimonidine tartrate, a relatively selective alpha-2 adrenergic
- Rednes Relief - mirvaso
Indication: MIRVASO® (brimonidine) topical gel, 0 33%* is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older
|
|
|